The Lynx Group
Cholangiocarcinoma News

Web Exclusives

Web Exclusives — December 7, 2022
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Read More

Web Exclusives — December 7, 2022
Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.
Read More

Web Exclusives — December 7, 2022
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
Read More

Web Exclusives — December 7, 2022
Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.
Read More

Web Exclusives — November 22, 2022
The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.
Read More

Web Exclusives — November 22, 2022
A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.
Read More

Web Exclusives — November 15, 2022
Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.
Read More

Web Exclusives — November 15, 2022
Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
Read More

Web Exclusives — October 11, 2022
Helsinn Therapeutics, Inc. has released an important announcement about the discontinuation of distribution of TRUSELTIQ® (infigratinib) capsules as of the first quarter of 2023. It is important to note that this discontinuation is not for safety or efficacy reasons but is based on difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial.
Read More

Web Exclusives — March 22, 2022
The current standard first-line therapy for advanced cholangiocarcinoma (CCA) is the chemotherapy combination of gemcitabine plus cisplatin; only about 40% of patients are amenable to surgery.
Read More

Page 1 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: